Azitra, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Azitra, Inc. (AZTR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 40.00 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-03-15
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 0.00 shares.
- Azitra, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 40.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 40.00K shares 10-K · filed 2024-03-15 | |
| 2023-09-30 | 40.00K shares 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |